Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

A phase 3, randomized, open-label, multicenter study of sonrotoclax (BGB-11417) plus anti-CD20 antibody therapies vs venetoclax plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL-RR1/CELESTIAL-RRCLL)

Blood (2025) 146 (Supplement 1): 2137.

https://doi.org/10.1182/blood-2025-2137

Published: 2025

Journal Articles

Nemtabrutinib plus venetoclax in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the dose escalation and confirmation segment of the Phase 3 bellwave-010 study

Paolo Ghia, Mauricio Chandia Cabas, Vernon Johan Louw, Maria Del Carmen Martinez Chamorro, Gonzalo Garate, Valeria Buccheri, Raimundo Gazitua Pepper, Alejandro Berkovits, Michael Cass, Eva Gonzalez Barca, Jose D. Sandoval-Sus, Muhit Ozcan, Sven Erik Ojavee, Ima Paydar, Mohammed Z.H. Farooqui, Ohad Benjamini

Blood (2025) 146 (Supplement 1): 2119.

https://doi.org/10.1182/blood-2025-2119

Published: 2025

Journal Articles

Concomitant use of venetoclax 100 mg and ketoconazole, a strong CYP3A4 inhibitor, is clinically equivalent to venetoclax 400 mg for treating relapsed or refractory chronic lymphocytic leukemia (CLL): A real-world analysis from the brazilian CLL registry.“

Gabriel Cunha, Pedro Perez, Fernanda Marques, Verena Pfister, Rodrigo Santucci, Milton Aranha, Danielle De Farias, Talita Silveira, Jayr Schmidt Filho, Valeria Buccheri, Roberto Silva, Leila Perobelli, Glaciano Ribeiro, Maura Colturato, Nelson Hamerschlak, Pedro Fernandes, Fernanda Santos Azevedo, Carlos Chiattone, Celso Arrais-Rodrigues

Blood (2025) 146 (Supplement 1): 3909.

https://doi.org/10.1182/blood-2025-3909

Published: 2025

Journal Articles

Baseline clinical characteristics of patients with chronic lymphocytic leukemia (CLL) from 11 Latin American countries: A real-world registry analysis

Ana Oliver, Celso Arrais-Rodrigues, Luis Mario Villela Martinez, Macarena Roa, Sofía Rivarola, Lorena Cardozo, Marialejandra Torres Viera, Denisse Castro, Fabiola Valvert, Daniela Trujillo Loaiza, Anelys García Salgado, Victoria Irigoin, Leila Perobelli, Silvana Cigliari, Alana von Glasenapp, Camila Peña, Sally Paredes, Valeria Buccheri, Virginia Lema Spinelli, Augusto Mirolli, Jose Alvarez, Maura Colturato, Ana Ines Landoni, Gislaine Duarte, Marta Zerga, Sabrina ranero Ferrari, Miguel Pavlovsky, Nancy Cristaldo, Laura Fogliatto, Maria Del Rosario Custidiano, Danielle De Farias, Maria Orlova, Fernando Barroso Duarte, Etelvina Macchiavello, Julio Pose Cabarcos, Sérgio Fortier, Julia Laviano, Clarisa Pagano Vilar, Nelson Hamerschlak, Vera Figueiredo, Fernando Pérez-Jacobo, Javier Retamales, Arianna Robles, German Stemmelin, Rosa Rios Jimenez, Henry Quintero, Brady Beltran, Jorge Castillo, Carlos Chiattone, Luis Malpica

Blood (2025) 146 (Supplement 1): 3908.

https://doi.org/10.1182/blood-2025-3908

Published: 2025

Journal Articles

Frontline therapy patterns and outcomes in chronic lymphocytic leukemia: A real-world, multicenter analysis from Latin America.

Celso Arrais-Rodrigues, Ana Oliver, Maria Cugliari, Luis Mario Villela Martinez, Macarena Roa, Lorena Cardozo, Marialejandra Torres Viera, Denisse Castro, Daniela Trujillo Loaiza, Leila Perobelli, Anelys García Salgado, Victoria Irigoin, Sofía Rivarola, Virginia Lema Spinelli, Jose Alvarez, Alana von Glasenapp, Camila Peña, Sally Paredes, Valeria Buccheri, Gislaine Duarte, Maura Colturato, Laura Fogliatto, Ana Ines Landoni, Sabrina ranero Ferrari, Augusto Mirolli, Marta Zerga, Miguel Pavlovsky, Nancy Cristaldo, Maria Del Rosario Custidiano, Fernando Pérez-Jacobo, Danielle De Farias, Maria Orlova, Julio Pose Cabarcos, Fernando Barroso Duarte, Etelvina Macchiavello, Sérgio Fortier, Julia Laviano, Clarisa Pagano Vilar, Nelson Hamerschlak, Vera Figueiredo, Rosa Rios Jimenez, Arianna Robles, Javier Retamales, Melanie Otañez, German Stemmelin, Henry Idrobo, Brady Beltran, Jorge Castillo, Luis Malpica, Carlos Chiattone

Blood (2025) 146 (Supplement 1): 2775.

https://doi.org/10.1182/blood-2025-2775

Published: 2025

Journal Articles

First-line venetoclax-based regimens versus chemoimmunotherapy in chronic lymphocytic leukemia: A real-world analysis from the brazilian CLL registry

Samir Nabhan, Gabriel Cunha, Verena Pfister, Leila Perobelli, Erika Oshiro, Rodrigo Santucci, Milton Aranha, Talita Silveira, Jayr Schmidt Filho, Danielle De Farias, Cristiana Solza, Valeria Buccheri, Thiago Carneiro, Vera Figueiredo, Maura Colturato, Abel Costa, Fernanda Marques, Caio Cesar Justino, Celso Arrais-Rodrigues

Blood (2025) 146 (Supplement 1): 7413.

https://doi.org/10.1182/blood-2025-7413

Published: 2025

Journal Articles

Real-World Analysis of Patients with CLL Treated with Ibrutinib: A Retrospective Analysis of the Brazilian Registry of CLL

Verena Pfister, Fernanda de Morais Marques, Vinicius Campos de Molla, Flavia Parra, Mihoko Yamamoto, Rodrigo Santucci, Milton A. F. Aranha, Valeria Buccheri, Glaciano Ribeiro, Vera Figueiredo, Nelson Hamerschlak, Abel Costa Neto, Jayr Schmidt Filho, Talita Silveira, Adriana Scheliga, Matheus Vescovi Goncalves, Leila Perobelli, Carlos Chiattone, Celso Arrais-Rodrigues

Blood (2024) 144 (Supplement 1): 2348.

https://doi.org/10.1182/blood-2024-210706

Published: 2024

Journal Articles

Outcomes of Conservative Indication Criteria for First-Line Treatment in Chronic Lymphocytic Leukemia: Insights from the Brazilian Registry of CLL

Blood (2023) 142 (Supplement 1): 6534.

https://doi.org/10.1182/blood-2023-190590

Published: 2023

Journal Articles

Contribution of Genetic Screening to the Diagnosis of Patients with Bone Marrow Failure and Short Telomeres

Thaís B. Barbosa Rodrigues, Thales D.M. Pereira, Valeria Buccheri, Flavia Donaires, Andre L.P. Santos, Denise C. Paranaguá-Vezozzo, Vanderson Rocha, Rodrigo T. Calado, Elvira Deolinda Rodrigues Pereira Velloso

Blood (2023) 142 (Supplement 1): 5658.

https://doi.org/10.1182/blood-2023-185133

Published: 2023

Journal Articles

External Validation of the Advanced-Stage Hodgkin Lymphoma International Prognostic Index (A-HIPI): Strong Calibration in the Brazilian Prospective Hodgkin Lymphoma Registry

Blood (2023) 142 (Supplement 1): 6200.

https://doi.org/10.1182/blood-2023-173318

Published: 2023

Journal Articles

Real-World Outcomes of Second-Line Chronic Lymphocytic Leukemia Treatments: Retrospective Analysis of the Brazilian Registry of CLL

Marcelo Pitombeira de Lacerda, Fernanda de Morais Marques, Verena Pfister, Flavia de Carvalho Parra, Vinicius Campos de Molla, Valeria Buccheri, Rafael Dezen Gaiolla, Laura Maria Fogliatto, Rodrigo Santucci, Marcelo Bellesso, Sérgio Costa Fortier, Talita M.B. Silveira, Glaciano Ribeiro, Nelson Hamerschlak, Mihoko Yamamoto, Matheus Vescovi Goncalves, Carlos S. Chiattone, Celso Arrais-Rodrigues

Blood (2022) 140 (Supplement 1): 7041–7042.

https://doi.org/10.1182/blood-2022-170872

Published: 2022

Journal Articles

Concerns about Prognostic Meaning of Quantitative PET Analysis in Classical Hodgkin Lymphoma

Fernanda Maria Maria Santos, Jose Flavio Gomes Marin, Marcos Santos Lima, Wellington F Silva, Rodrigo D Velasques, Ana Carolina Arrais Maia, Marcelo Junqueira Atanazio, Lucas Bassolli de Oliveira Alves, Frederico Rafael Moreira, Carlos Alberto Buchpiguel, Valeria Buccheri, Vanderson Rocha

Blood (2022) 140 (Supplement 1): 6586–6587.

https://doi.org/10.1182/blood-2022-167663

Published: 2022

Journal Articles

Ezrin Is a Potential Druggable Target in Chronic Lymphocytic Leukemia

Jean Carlos Lipreri Da Silva, Felipe Saldanha-Araujo, Raphael Costa Bandeira de Melo, Hugo Passos Vicari, Amandda Évelin Silva De Carvalho, Eduardo M Rego, Valeria Buccheri, João Agostinho Machado-Neto

Blood (2022) 140 (Supplement 1): 12359–12360.

https://doi.org/10.1182/blood-2022-160267

Published: 2022

Journal Articles

Effect of Pembrolizumab Monotherapy Versus Brentuximab Vedotin (BV) on Symptoms Associated with Health-Related Quality of Life (HRQoL) in Relapsed/Refractory (R/R) Classical Hodgkin Lymphoma (cHL) in the Randomized, Phase 3, Keynote-204 Study

Pier Luigi Zinzani, MD, Radhakrishnan Ramchandren, Armando Santoro, Ewa Paszkiewicz-Kozik, Robin Gasiorowski, Nathalie A Johnson, MD PhD, José S. R. de Oliveira, Valeria Buccheri, Guilherme Fleury Perini, Michael Dickinson, DMed Sci, Andrew McDonald, Muhit Ozcan, Naohiro Sekiguchi, Monika Raut, Hilde Giezek, Akash Nahar, John Kuruvilla, MD

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-139416

Published: 2020

Journal Articles

Effect of Pembrolizumab (Pembro) Monotherapy Versus Brentuximab Vedotin (BV) on Patients (Pts) with Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL): Exploratory Analysis of the Randomized, Phase 3 Keynote-204 Study By Prior Lines of Therapy

John Kuruvilla, MD, Radhakrishnan Ramchandren, Armando Santoro, Ewa Paszkiewicz-Kozik, Robin Gasiorowski, Nathalie A Johnson, MD PhD, Laura Maria Fogliatto, Iara Goncalves, José de Oliveira, Valeria Buccheri, Guilherme Fleury Perini, Neta Goldschmidt, Irina Kryachok, Naohiro Sekiguchi, Jianxin Lin, Akash Nahar, Patricia Marinello, Pier Luigi Zinzani, MD

Blood (2020) 136 (Supplement 1): 12.

https://doi.org/10.1182/blood-2020-142565

Published: 2020

Journal Articles

Favorable Outcome in CLL Patients Not Treated Despite Presenting Iwcll Criteria: A Retrospective Analysis of the Brazilian CLL Group

Fernanda de Morais Marques, Verena Pfister, Flavia Parra, Mihoko Yamamoto, MD PhD, Rodrigo Santucci Silva, MD, Marcelo Bellesso, MD, Vinicius Campos de Molla, MD, Ana Rita Da Fonseca, MD, Yana Novis, MD, Sérgio Costa Fortier, MD, Talita Silveira, MD PhD, Guilherme Brasil Duffles Amarante, MD, Valeria Buccheri, Matheus Vescovi, MD PhD, Carlos Sérgio Chiattone, MD PhD, Celso Arrais, MD PhD

Blood (2020) 136 (Supplement 1): 12.

https://doi.org/10.1182/blood-2020-142810

Published: 2020

Journal Articles

Comparison of Clinical and Laboratory Features, Drug Availability, and Outcomes of CLL Patients Treated in Public or in Private Hospitals in Brazil: A Retrospective Analysis of the Brazilian Registry of CLL

Blood (2020) 136 (Supplement 1): 2.

https://doi.org/10.1182/blood-2020-142520

Published: 2020

Journal Articles

Retrospective Comparison between MEC and FLAG-Ida Regimens for Refractory or Relapsed Acute Myeloid Leukemia in Adults

Wellington F Silva, MD, Lidiane Inês Da Rosa, MD, Fernanda S Seguro, MD, Douglas R. A. Silveira, Luciana Nardinelli, M.Sc, Valeria Buccheri, MD PhD, Elvira DRP Velloso, MD PhD, Vanderson Rocha, MD PhD, Eduardo M Rego, MD PhD

Blood (2019) 134 (Supplement_1): 1354.

https://doi.org/10.1182/blood-2019-127202

Published: 2019

Journal Articles

Ibrutinib Maintenance after Chemoimmunotherapy Is Feasible and Results in Excellent Progression-Free and Overall Survival in Patients with Detectable MRD after Chemoimmunotherapy

Nayara Ribeiro Guedes, MD, Ana Rita Da Fonseca, MD, Thiago Xavier Carneiro, MD PhD, Vinicius Campos de Molla, MD, Rodrigo Santucci Silva, MD, Sérgio Costa Fortier, MD, Vera Lucia de Piratininga Figueiredo, MD, Larissa Ommati, MD, Valeria Buccheri, MD PhD, Gislaine Borba Oliveira, MD, Leila Martins Perobelli, MD, Fernando Sergio Blumm Ferreira, MD, Matheus Vescovi, MD PhD, Celso Arrais-Rodrigues, MD PhD

Blood (2019) 134 (Supplement_1): 1764.

https://doi.org/10.1182/blood-2019-125626

Published: 2019

Journal Articles

WHO-2016 Classification in ALL By Cytogenetics, FISH and Molecular Biology - Experience of Two Reference Centers in Brazil

Elvira DRP Velloso, MD PhD, Maria Gabriella Cordeiro, Danielle Lucon, PhD, Renata Kishimoto, Aline Medeiros Leal, PhD, Ana Carolina Arrais Maia, MD, Valeria Buccheri, MD PhD, Israel Bendit, MD PhD, Wellington Fernandes Silva, Jr., MD, Cristovao Mangueira, MD PhD, Eduardo Magalhães Rego, MD PhD, Vanderson Rocha, MD PhD

Blood (2018) 132 (Supplement 1): 5288.

https://doi.org/10.1182/blood-2018-99-115426

Published: 2018

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

A phase 3, randomized, open-label, multicenter study of sonrotoclax (BGB-11417) plus anti-CD20 antibody therapies vs venetoclax plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL-RR1/CELESTIAL-RRCLL)

Nemtabrutinib plus venetoclax in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the dose escalation and confirmation segment of the Phase 3 bellwave-010 study

Concomitant use of venetoclax 100 mg and ketoconazole, a strong CYP3A4 inhibitor, is clinically equivalent to venetoclax 400 mg for treating relapsed or refractory chronic lymphocytic leukemia (CLL): A real-world analysis from the brazilian CLL registry.“

Baseline clinical characteristics of patients with chronic lymphocytic leukemia (CLL) from 11 Latin American countries: A real-world registry analysis

Frontline therapy patterns and outcomes in chronic lymphocytic leukemia: A real-world, multicenter analysis from Latin America.

First-line venetoclax-based regimens versus chemoimmunotherapy in chronic lymphocytic leukemia: A real-world analysis from the brazilian CLL registry

Real-World Analysis of Patients with CLL Treated with Ibrutinib: A Retrospective Analysis of the Brazilian Registry of CLL

Outcomes of Conservative Indication Criteria for First-Line Treatment in Chronic Lymphocytic Leukemia: Insights from the Brazilian Registry of CLL

Contribution of Genetic Screening to the Diagnosis of Patients with Bone Marrow Failure and Short Telomeres

External Validation of the Advanced-Stage Hodgkin Lymphoma International Prognostic Index (A-HIPI): Strong Calibration in the Brazilian Prospective Hodgkin Lymphoma Registry

Real-World Outcomes of Second-Line Chronic Lymphocytic Leukemia Treatments: Retrospective Analysis of the Brazilian Registry of CLL

Concerns about Prognostic Meaning of Quantitative PET Analysis in Classical Hodgkin Lymphoma

Ezrin Is a Potential Druggable Target in Chronic Lymphocytic Leukemia

Effect of Pembrolizumab Monotherapy Versus Brentuximab Vedotin (BV) on Symptoms Associated with Health-Related Quality of Life (HRQoL) in Relapsed/Refractory (R/R) Classical Hodgkin Lymphoma (cHL) in the Randomized, Phase 3, Keynote-204 Study

Effect of Pembrolizumab (Pembro) Monotherapy Versus Brentuximab Vedotin (BV) on Patients (Pts) with Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL): Exploratory Analysis of the Randomized, Phase 3 Keynote-204 Study By Prior Lines of Therapy

Favorable Outcome in CLL Patients Not Treated Despite Presenting Iwcll Criteria: A Retrospective Analysis of the Brazilian CLL Group

Comparison of Clinical and Laboratory Features, Drug Availability, and Outcomes of CLL Patients Treated in Public or in Private Hospitals in Brazil: A Retrospective Analysis of the Brazilian Registry of CLL

Retrospective Comparison between MEC and FLAG-Ida Regimens for Refractory or Relapsed Acute Myeloid Leukemia in Adults

Ibrutinib Maintenance after Chemoimmunotherapy Is Feasible and Results in Excellent Progression-Free and Overall Survival in Patients with Detectable MRD after Chemoimmunotherapy

WHO-2016 Classification in ALL By Cytogenetics, FISH and Molecular Biology - Experience of Two Reference Centers in Brazil

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only